CN111386113A - 包含lsz102和阿培利司的药物组合 - Google Patents

包含lsz102和阿培利司的药物组合 Download PDF

Info

Publication number
CN111386113A
CN111386113A CN201880076600.2A CN201880076600A CN111386113A CN 111386113 A CN111386113 A CN 111386113A CN 201880076600 A CN201880076600 A CN 201880076600A CN 111386113 A CN111386113 A CN 111386113A
Authority
CN
China
Prior art keywords
day
lsz102
amide
pharmaceutically acceptable
pharmaceutical combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880076600.2A
Other languages
English (en)
Chinese (zh)
Inventor
T·阿布拉姆斯
L·A·该赛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN111386113A publication Critical patent/CN111386113A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880076600.2A 2017-12-01 2018-11-29 包含lsz102和阿培利司的药物组合 Pending CN111386113A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762593760P 2017-12-01 2017-12-01
US62/593,760 2017-12-01
US201862771757P 2018-11-27 2018-11-27
US62/771,757 2018-11-27
PCT/IB2018/059470 WO2019106604A1 (en) 2017-12-01 2018-11-29 Pharmaceutical combination comprising lsz102 and alpelisib

Publications (1)

Publication Number Publication Date
CN111386113A true CN111386113A (zh) 2020-07-07

Family

ID=64901034

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880076600.2A Pending CN111386113A (zh) 2017-12-01 2018-11-29 包含lsz102和阿培利司的药物组合

Country Status (6)

Country Link
US (2) US10695333B2 (cg-RX-API-DMAC7.html)
EP (1) EP3716969A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021504384A (cg-RX-API-DMAC7.html)
CN (1) CN111386113A (cg-RX-API-DMAC7.html)
TW (1) TW201924675A (cg-RX-API-DMAC7.html)
WO (1) WO2019106604A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11179365B2 (en) 2017-11-16 2021-11-23 Novartis Ag Pharmaceutical combination comprising LSZ102 and ribociclib
DK3847157T3 (da) 2018-09-07 2022-08-08 Sanofi Sa Fremgangsmåde til fremstilling af methyl-[6-(2,4-dichlorphenyl)-5-[4-[(3s)-1-(3-fluorpropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulen-2-carboxylat] og salt deraf
EP3849545A1 (en) * 2018-09-10 2021-07-21 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of neurofibromatosis
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
CA3160897A1 (en) 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司(alpelisib)與6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧苯基]-8,9-二氫-7h-苯并[7]輪烯-2-羧酸之組合
IL302153B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
IL302152B1 (en) 2020-10-19 2026-07-01 Sanofi Sa 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523253A (ja) * 2013-06-19 2016-08-08 セラゴン ファーマシューティカルズ, インク. エストロゲン受容体モジュレーター及びその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2618489A1 (en) 2005-09-07 2007-03-15 Laboratoires Serono S.A. Pi3k inhibitors for the treatment of endometriosis
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
EP2650401A1 (de) 2012-04-10 2013-10-16 Siemens Aktiengesellschaft Kraftwerk basiertes Methanisierungssystem
NZ710385A (en) * 2013-02-19 2016-10-28 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
EP4772247A2 (en) 2013-08-14 2026-07-08 Novartis AG Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
WO2015028409A1 (de) 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
JP6223154B2 (ja) 2013-11-29 2017-11-01 ロッテ アドバンスト マテリアルズ カンパニー リミテッド ポリアミド樹脂およびその製造方法
SG11201607334YA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
MX384605B (es) 2015-04-29 2025-03-14 Radius Pharmaceuticals Inc Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
AU2016287189A1 (en) * 2015-06-29 2017-10-12 F. Hoffmann-La Roche Ag Methods of treatment with taselisib
CN108472289A (zh) * 2015-11-02 2018-08-31 诺华股份有限公司 磷脂酰肌醇3-激酶抑制剂的给药方案
JP7084875B2 (ja) * 2016-03-29 2022-06-15 ノバルティス アーゲー 水-界面活性剤混合物を含む反応媒体
JP7229162B2 (ja) 2017-01-06 2023-02-27 ジー1 セラピューティクス, インコーポレイテッド 癌の治療に対する併用療法
US11179365B2 (en) * 2017-11-16 2021-11-23 Novartis Ag Pharmaceutical combination comprising LSZ102 and ribociclib

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523253A (ja) * 2013-06-19 2016-08-08 セラゴン ファーマシューティカルズ, インク. エストロゲン受容体モジュレーター及びその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS.GOV: "Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers", 《HTTPS://CLINICALTRIALS.GOV/CT2/SHOW/NCT02734615》 *

Also Published As

Publication number Publication date
EP3716969A1 (en) 2020-10-07
US10695333B2 (en) 2020-06-30
US20190167652A1 (en) 2019-06-06
JP2021504384A (ja) 2021-02-15
WO2019106604A1 (en) 2019-06-06
US20210000810A1 (en) 2021-01-07
TW201924675A (zh) 2019-07-01

Similar Documents

Publication Publication Date Title
US10695333B2 (en) Pharmaceutical combination comprising LSZ102 and alpelisib
EP3923941B1 (en) Pharmaceutical combination comprising tno155 and ribociclib
EP2739153B1 (en) Treatment of breast cancer
EP2827859B1 (en) Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders
US20220031657A1 (en) Pharmaceutical combination comprising lsz102 and ribociclib
AU2018234903B2 (en) Combination therapies for the treatment of breast cancer
AU2019407159A1 (en) Combination therapy with a Raf inhibitor and a CKD4/6 inhibitor for use in the treatment of cancer
WO2016061253A1 (en) Drug combination to treat melanoma
KR20200138303A (ko) 다브라페닙, 트라메티닙 및 erk 저해제를 포함하는 삼중 약제학적 조합물
CN117177752A (zh) 用于治疗mpnst的化合物和组合物
CN115916209A (zh) 用于治疗PRC2介导的疾病或障碍的N-((5-氟-2,3-二氢苯并呋喃-4-基)甲基)-8-(2-甲基吡啶-3-基)-[1,2,4]三唑并[4,3-c]嘧啶-5-胺或其药学上可接受的盐的给药方案
KR100576157B1 (ko) 비만 예방 또는 치료용 약학 조성물
WO2023172909A1 (en) Compositions comprising anti-progestins and selective estrogen receptor modulators and methods of using the same
JP2026516050A (ja) 多発性硬化症を治療するためのbtk阻害剤
TW202543608A (zh) Kras g12c抑制劑之治療用途
CN118660706A (zh) Cdk4和6抑制剂与氟维司群组合用于在cdk4和6抑制剂先前治疗的患者中治疗激素受体阳性、人表皮生长因子受体2阴性晚期或转移性乳腺癌
HK1198867B (en) Treatment of breast cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200707